Education
About Us
Working with TipRanks
Follow Us
Immucell Corp. (ICCC)
NASDAQ:ICCC
Earnings Data
Report Date
May 20, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
―Last Year’s EPS
0.16Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed a broadly positive operational and strategic turnaround: revenue grew 4.3% for the year, gross margins materially improved (41% vs 30% prior year), operating income swung to $1.6M from a loss, manufacturing capacity expanded and backorders were resolved, and management has doubled down on the high-margin First Defense franchise with commercial investments underway. Notable negatives include a $2.7M Re-Tain impairment, ~$650K of inventory write-downs, a remaining net loss of $1.0M, international timing-related weakness, and execution risk associated with planned capacity/yield improvements. Overall the positives (margin expansion, operating income turnaround, strategic focus and market opportunity) outweigh the negatives, though investors should monitor execution on capacity expansion and the impact of prior write-downs.Company Guidance
Revenue Growth for Full Year 2025
Total product sales of $27.6 million in 2025, representing a 4.3% increase versus 2024. Q4 product sales were $7.6 million (a modest 1.6% decline year-over-year, noted as impacted by prior-period catch-up sales).
Domestic Sales Strength
Domestic Q4 sales grew 8.7% year-over-year to $7.0 million, driving the majority of 2025 growth while international sales were a smaller portion of total sales (~8% of Q4 sales).
Material Gross Margin Improvement
Full year gross margin improved to 41% in 2025 versus 30% in 2024 (an 11 percentage-point increase). Q4 gross margin was 38% versus 37% in Q4 2024, driven by higher manufacturing volumes, efficiencies and product price increases.
Operating Profit Turnaround
Operating income of $1.6 million in 2025 versus an operating loss of $1.6 million in 2024 — a year-over-year improvement of $3.3 million. This reflects margin improvement and higher sales.
Manufacturing Capacity Expansion & Backorder Resolution
Manufacturing capacity expanded from ~3.0 million units in 2023 to ~4.6 million units in 2025. Company resolved a multiyear backorder situation, normalized finished goods (working capital rose from $10.6M to $13.0M), and plans identified to increase capacity to 5–6 million units via yield and process improvements.
Strategic Focus on First Defense and Market Opportunity
Company pivoted to focus on the First Defense franchise. First Defense increased treated-animal share from ~10% to ~15% over eight years, capturing ~29% of category spend. U.S. scours category spend was ~$93 million in 2025 (up 14% vs 2024), and management estimates U.S. total addressable market >$200 million with international TAM at least ~5x larger.
Product Differentiation and Commercial Investment
First Defense (colostrum-derived) provides 3–6x neutralizing antibodies versus the primary vaccine competitor and is the only USDA-approved non-vaccine solution in this space; product is priced at ~2.5x alternatives. Management increased commercial capacity (hired senior international market development leader, added a U.S. sales manager, recruiting a third commercial role) and rolled out a standardized sales approach to scale commercialization.
Improved Net Loss and EPS
Net loss of $1.0 million in 2025, an improvement of $1.1 million year-over-year. Basic net loss per share of approximately $0.12 in 2025 versus a net loss of $0.26 per share in 2024.
ICCC Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ICCC Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 04, 2026 | $6.46 | $6.35 | -1.70% |
Nov 13, 2025 | $6.05 | $5.40 | -10.74% |
Aug 14, 2025 | $6.72 | $6.10 | -9.18% |
May 14, 2025 | $4.91 | $5.30 | +7.94% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Immucell Corp. (ICCC) report earnings?
Immucell Corp. (ICCC) is schdueled to report earning on May 20, 2026, After Close (Confirmed).
What is Immucell Corp. (ICCC) earnings time?
Immucell Corp. (ICCC) earnings time is at May 20, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ICCC EPS forecast?
Currently, no data Available